Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541381 · ClinicalTrials.gov registry record · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
A NA study of Breast Cancer and Head and Neck Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 860
- Enrollment target
- 1
- Study location
NCT04541381 is a NA study of Breast Cancer and Head and Neck Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 860 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04541381, a NA study of Breast Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 860 participants
- Enrollment target
- 1
- Study location
Study Summary
Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects. Doctors leading the study will collect genetic information from study participants using pharmacogenomics/genotyping. Pharmacogenomics is the study of how the differences in our genes can affect our unique response to medications. This is a randomized study, which means that participants in this study will be randomly assigned (as if "by flip of a coin") to one of two different groups: a "pharmacogenomics group" or "control group".
Conditions Studied
Interventions
- OTHER Availability of clinical decision support based on pharmacogenomic results.
Study Locations (1)
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04541381
The ClinicalTrials.gov registry entry for NCT04541381 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (69% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Availability of clinical decision support based on pharmacogenomic results. is the first listed.
NCT04541381 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04541381 about?
NCT04541381 is a clinical study titled "The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care". Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects. Doctors leading the study will collect genetic information from study participants...
What is the current status of trial NCT04541381?
This trial is currently recruiting. It is a NA study. The enrollment target is 860 participants. The study started on 2022-02-07. Estimated completion is 2028-03-31.
What conditions does trial NCT04541381 study?
This clinical trial studies the following conditions: Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation.
What interventions are being tested in trial NCT04541381?
The interventions under investigation include: Availability of clinical decision support based on pharmacogenomic results. (OTHER).
Who is sponsoring clinical trial NCT04541381?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04541381 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.